Aimmune Therapeutics (AIMT) Receiving Positive News Coverage, Analysis Shows
News headlines about Aimmune Therapeutics (NASDAQ:AIMT) have been trending positive this week, Accern reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aimmune Therapeutics earned a news impact score of 0.32 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.6022519350206 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Aimmune Therapeutics, Inc. (AIMT) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Aimmune Therapeutics, Inc. (NASDAQ: AIMT) – Why Day Traders Usually Trade on In Play Stocks? – Alpha Beta Stock (alphabetastock.com)
- Notable Stocks in Focus: Infinity Pharmaceuticals, Inc., (NASDAQ: INFI), Aimmune Therapeutics, Inc., (NASDAQ: AIMT … – Stocks In The News (press release) (tradingnewsnow.com)
- An Eye on Data – Aimmune Therapeutics, Inc., (NASDAQ: AIMT) – Stock Watch (stocksnewstimes.com)
- Aimmune Therapeutics, Inc. (AIMT) Insider Sells $62,865.00 in Stock (americanbankingnews.com)
A number of research firms have commented on AIMT. Credit Suisse Group raised their target price on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Zacks Investment Research cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Wedbush restated an “ourperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, August 14th. Finally, Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $46.75.
Aimmune Therapeutics (NASDAQ AIMT) traded down $0.51 during trading on Friday, hitting $34.77. 89,065 shares of the stock traded hands, compared to its average volume of 780,645. Aimmune Therapeutics has a 52-week low of $15.97 and a 52-week high of $37.50.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.09. sell-side analysts expect that Aimmune Therapeutics will post -2.63 EPS for the current year.
In related news, CEO Stephen George Dilly sold 100,000 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $25.01, for a total value of $2,501,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Douglas T. Sheehy sold 47,425 shares of the firm’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the completion of the transaction, the insider now directly owns 34,300 shares of the company’s stock, valued at $1,181,292. The disclosure for this sale can be found here. In the last quarter, insiders have sold 317,720 shares of company stock worth $8,400,244. Company insiders own 24.56% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://theolympiareport.com/2017/11/17/aimmune-therapeutics-aimt-receiving-positive-news-coverage-analysis-shows.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.